News | Radiation Therapy | August 23, 2016

IBA Shares Worldwide First Clinical Application of Dolphin Transmission Detector

Radiation therapy clinic in Bayreuth, Germany has clinically implemented Dolphin, which provides higher treatment dose measurement resolution and detection of possible dose discrepancies

IBA, Klinikum Bayreuth Germany, first clinical application, Dolphin Transmission Detector, quality assurance, radiation therapy

August 23, 2016 — IBA (Ion Beam Applications S.A.) announced the first worldwide clinical implementation of its newly released Dolphin Online Ready Patient QA and Monitoring. The team at the Radiation Therapy department of the Klinikum Bayreuth GmbH in Bayreuth, Germany, has successfully validated and clinically implemented three Dolphin systems at two of their sites.

This milestone allows the clinic to set a trend in terms of radiation therapy treatment quality. Compared to conventional quality assurance (QA) solutions, Dolphin provides a significantly higher treatment dose measurement resolution and capability to detect and verify possible dose discrepancies. Patient QA workflow efficiency is increased with Dolphin’s “plug and play” wireless design and instant setup.

“We are proud to provide the highest level of treatment quality and safety to all our patients. Prior to each patient treatment, an intensive quality assurance is performed with Dolphin. This is our basis to achieve the highest QA standards today and in the future,” said Mathias Dierl, head of medical physics at the Klinikum Bayreuth.

The Dolphin dose measurements are analyzed with a sophisticated TPS-Class verification software package; the instant verification functionality provides automatic analysis and displays an “OK” message for the tests that have successfully passed. The clinical relevance of the patient dose discrepancies can be comprehensively determined in 3-D patient anatomy with DVH and Oran-at-Risk pass/fail analysis.

At the clinic in Bayreuth, highly complex intensity-modulated radiation therapy (IMRT) treatment plans are delivered and measured with Dolphin prior to each patient treatment. The sophisticated TPS-Class software allows verification of dose deviations in 3-D between the plan and delivered, as well as Dolphin-measured actual dose in the patient’s anatomy.

For more information:

Related Content

Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...